Olix Pharmaceuticals (KRX: 226950)
Who is buying Olix Pharmaceuticals?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩46.7bn ($35M) of Olix Pharmaceuticals, the 19th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net bought ₩71.0bn ($53M) and retail investors net sold ₩16.2bn ($12M) over the same window. Foreigners were net buyers on 8 of the 20 sessions.
Foreign investors hold 9.1% of Olix Pharmaceuticals' listed shares (KRX ownership data as of Oct 13, 2026), down from 11% twenty sessions earlier and 6.67% a year ago.
The stock closed at ₩91,000 on Oct 13, 2026: -8.27% over 20 sessions, -35.19% year-to-date, -1.41% over one year. The 52-week range is ₩84,000 – ₩217,000.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩91,000 | ₩-5.6bn | ₩-7.6bn | +₩13.1bn |
| 2026-10-12 | ₩106,200 | ₩-1.4bn | +₩1.6bn | ₩-0.3bn |
| 2026-10-08 | ₩117,300 | ₩-8.1bn | +₩5.7bn | +₩2.6bn |
| 2026-10-07 | ₩122,700 | ₩-10.8bn | +₩10.6bn | +₩0.5bn |
| 2026-10-06 | ₩122,600 | ₩-9.6bn | +₩10.3bn | +₩3.5bn |
| 2026-10-02 | ₩116,800 | ₩-6.4bn | +₩3.7bn | +₩2.5bn |
| 2026-10-01 | ₩116,900 | +₩4.2bn | +₩19.9bn | ₩-23.9bn |
| 2026-09-30 | ₩102,500 | +₩0.0bn | +₩1.9bn | ₩-1.9bn |
| 2026-09-29 | ₩102,800 | ₩-0.9bn | ₩-0.7bn | +₩1.9bn |
| 2026-09-28 | ₩104,400 | ₩-2.4bn | +₩6.1bn | ₩-3.9bn |
| 2026-09-23 | ₩102,700 | +₩2.4bn | ₩-4.5bn | +₩2.0bn |
| 2026-09-22 | ₩102,200 | +₩4.1bn | ₩-9.5bn | +₩5.6bn |
| 2026-09-21 | ₩106,100 | +₩12.5bn | ₩-7.5bn | ₩-3.5bn |
| 2026-09-18 | ₩111,600 | +₩0.4bn | +₩2.8bn | ₩-3.0bn |
| 2026-09-17 | ₩114,200 | ₩-5.5bn | +₩4.9bn | ₩-0.1bn |
| 2026-09-16 | ₩111,100 | ₩-8.4bn | +₩8.5bn | +₩0.1bn |
| 2026-09-15 | ₩108,300 | +₩2.9bn | +₩13.4bn | ₩-15.5bn |
| 2026-09-14 | ₩100,100 | ₩-14.8bn | +₩5.3bn | +₩9.5bn |
| 2026-09-11 | ₩109,300 | ₩-1.8bn | +₩7.8bn | ₩-5.5bn |
| 2026-09-10 | ₩99,800 | +₩2.3bn | ₩-2.0bn | +₩0.1bn |
| 2026-09-09 | ₩99,200 | +₩0.1bn | ₩-0.7bn | +₩0.5bn |
| 2026-09-08 | ₩99,100 | +₩4.8bn | ₩-3.3bn | ₩-1.5bn |
| 2026-09-07 | ₩97,500 | +₩5.7bn | ₩-4.1bn | ₩-3.8bn |
| 2026-09-04 | ₩95,900 | +₩4.9bn | +₩0.0bn | ₩-4.6bn |
| 2026-09-03 | ₩91,800 | +₩5.6bn | ₩-14.7bn | +₩8.9bn |
| 2026-09-02 | ₩100,200 | +₩1.7bn | ₩-9.6bn | +₩8.1bn |
| 2026-09-01 | ₩105,500 | +₩0.8bn | ₩-1.6bn | +₩0.5bn |
| 2026-08-31 | ₩103,400 | ₩-0.3bn | ₩-2.8bn | +₩2.9bn |
| 2026-08-28 | ₩105,900 | ₩-2.8bn | +₩1.1bn | +₩1.6bn |
| 2026-08-27 | ₩104,800 | +₩8.8bn | +₩2.2bn | ₩-11.0bn |
| 2026-08-26 | ₩99,300 | ₩-1.3bn | ₩-2.5bn | +₩4.3bn |
| 2026-08-25 | ₩100,400 | ₩-0.6bn | ₩-0.8bn | +₩1.5bn |
| 2026-08-24 | ₩102,200 | +₩2.5bn | +₩1.3bn | ₩-3.7bn |
| 2026-08-21 | ₩98,100 | ₩-11.6bn | ₩-6.8bn | +₩18.2bn |
| 2026-08-20 | ₩109,400 | ₩-9.6bn | +₩10.1bn | ₩-0.5bn |
| 2026-08-19 | ₩104,400 | ₩-0.8bn | ₩-0.3bn | +₩1.0bn |
| 2026-08-18 | ₩106,500 | +₩8.1bn | ₩-8.1bn | ₩-0.7bn |
| 2026-08-14 | ₩112,000 | +₩6.1bn | ₩-9.3bn | +₩2.7bn |
| 2026-08-13 | ₩112,500 | +₩6.9bn | ₩-22.7bn | +₩15.8bn |
| 2026-08-12 | ₩113,500 | ₩-4.2bn | ₩-32.9bn | +₩37.7bn |
| 2026-08-11 | ₩131,900 | ₩-4.7bn | ₩-7.6bn | +₩12.1bn |
| 2026-08-10 | ₩137,800 | ₩-10.7bn | +₩19.0bn | ₩-8.8bn |
| 2026-08-07 | ₩121,200 | ₩-1.1bn | +₩0.2bn | +₩0.8bn |
| 2026-08-06 | ₩123,500 | ₩-7.5bn | +₩3.1bn | +₩4.3bn |
| 2026-08-05 | ₩121,500 | +₩0.6bn | +₩2.1bn | ₩-2.8bn |
| 2026-08-04 | ₩119,800 | ₩-11.7bn | +₩20.8bn | ₩-9.2bn |
| 2026-08-03 | ₩105,400 | ₩-1.5bn | +₩7.5bn | ₩-6.0bn |
| 2026-07-31 | ₩94,800 | +₩5.9bn | ₩-5.9bn | +₩0.4bn |
| 2026-07-30 | ₩89,500 | +₩5.0bn | ₩-5.4bn | +₩0.4bn |
| 2026-07-29 | ₩94,100 | +₩4.8bn | ₩-9.6bn | +₩6.4bn |
| 2026-07-28 | ₩107,000 | ₩-2.7bn | +₩7.6bn | ₩-2.7bn |
| 2026-07-27 | ₩113,700 | ₩-5.6bn | +₩9.0bn | ₩-3.4bn |
| 2026-07-24 | ₩109,500 | ₩-3.3bn | +₩6.3bn | ₩-3.0bn |
| 2026-07-23 | ₩113,800 | +₩8.0bn | ₩-0.5bn | ₩-7.8bn |
| 2026-07-22 | ₩103,000 | +₩10.3bn | ₩-10.1bn | +₩0.0bn |
| 2026-07-21 | ₩109,200 | +₩11.0bn | ₩-9.4bn | ₩-1.6bn |
| 2026-07-20 | ₩114,800 | ₩-2.8bn | ₩-9.4bn | +₩12.5bn |
| 2026-07-16 | ₩136,600 | ₩-6.8bn | ₩-5.6bn | +₩11.3bn |
| 2026-07-15 | ₩131,200 | +₩4.7bn | +₩0.4bn | ₩-9.2bn |
| 2026-07-14 | ₩123,700 | ₩-4.9bn | +₩1.3bn | +₩3.4bn |
| 2026-07-13 | ₩127,500 | +₩2.1bn | +₩6.3bn | ₩-8.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-5.6bn | $-4M | ₩-7.6bn | +₩13.1bn |
| 5 days | ₩-35.5bn | $-27M | +₩20.7bn | +₩19.4bn |
| 20 days | ₩-46.7bn | $-35M | +₩71.0bn | ₩-16.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Olix Pharmaceuticals stock?
Over the last 5 sessions foreign investors net sold ₩35.5bn ($27M) of Olix Pharmaceuticals; over 60 sessions they net sold ₩34.7bn ($26M); since Jan 1, 2026 they net sold ₩9.9bn ($7M). Over 20 sessions the stock is the 19th largest foreign net sale among 1828 KOSDAQ stocks.
How much of Olix Pharmaceuticals do foreign investors own?
Foreign investors own 9.1% of Olix Pharmaceuticals' shares as of Oct 13, 2026, versus 6.67% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩71.0bn ($53M) and retail investors net sold ₩16.2bn ($12M) of Olix Pharmaceuticals. Institutions are on the other side of foreign selling.
Is Olix Pharmaceuticals listed on KOSPI or KOSDAQ?
Olix Pharmaceuticals (올릭스) trades on KOSDAQ under KRX code 226950 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.6B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | – | – | -₩18bn (-$14M) | -₩19bn (-$14M) |
| 2024 | – | – | -₩31bn (-$23M) | -₩41bn (-$30M) |
| 2025 | – | – | -₩30bn (-$22M) | -₩16bn (-$12M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.